These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. PCSK9 antibodies: A new class of lipid-lowering drugs. Gouni-Berthold I Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300 [TBL] [Abstract][Full Text] [Related]
7. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement. Henne KR; Ason B; Howard M; Wang W; Sun J; Higbee J; Tang J; Matsuda KC; Xu R; Zhou L; Chan JC; King C; Piper DE; Ketchem RR; Michaels ML; Jackson SM; Retter MW J Pharmacol Exp Ther; 2015 Apr; 353(1):119-31. PubMed ID: 25653417 [TBL] [Abstract][Full Text] [Related]
8. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
9. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors. Shen L; Peng H; Xu D; Zhao S Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522 [TBL] [Abstract][Full Text] [Related]
10. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353 [TBL] [Abstract][Full Text] [Related]
11. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163 [TBL] [Abstract][Full Text] [Related]
12. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo. Schiele F; Park J; Redemann N; Luippold G; Nar H J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255 [TBL] [Abstract][Full Text] [Related]
13. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. Schroeder KM; Beyer TP; Hansen RJ; Han B; Pickard RT; Wroblewski VJ; Kowala MC; Eacho PI J Lipid Res; 2015 Nov; 56(11):2124-32. PubMed ID: 26392590 [TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
15. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Seidah NG Curr Pharm Des; 2013; 19(17):3161-72. PubMed ID: 23317404 [TBL] [Abstract][Full Text] [Related]
16. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]
17. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Alborn WE; Cao G; Careskey HE; Qian YW; Subramaniam DR; Davies J; Conner EM; Konrad RJ Clin Chem; 2007 Oct; 53(10):1814-9. PubMed ID: 17702855 [TBL] [Abstract][Full Text] [Related]
18. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol. Ling H; Burns TL; Hilleman DE Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905 [TBL] [Abstract][Full Text] [Related]
19. Low levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation. Tran-Dinh A; Levoye A; Lambert G; Louedec L; Journé C; Meilhac O; Amarenco P Stroke; 2014 Oct; 45(10):3086-8. PubMed ID: 25123222 [TBL] [Abstract][Full Text] [Related]